A carregar...
Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
Once initiated for pulmonary arterial hypertension (PAH), epoprostenol treatment usually needs to be delivered for an indefinite duration. It is possible that some participants could be transitioned from epoprostenol to oral therapies. We retrospectively evaluated eight PAH participants transitioned...
Na minha lista:
| Publicado no: | Pulm Circ |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5467933/ https://ncbi.nlm.nih.gov/pubmed/28597752 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045893217702401 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|